OncoZenge AB AI Stock Analysis
Want to see SE:ONCOZ full AI Analyst Report?
OncoZenge AB (ONCOZ) AI Stock Analysis
OncoZenge AB
(Nasdaq OMX AB:ONCOZ)
The score is driven primarily by substantial operating losses, declining revenue, and continued cash burn. Debt-free status offers limited financial support, but weak profitability, negative cash flow, unfavorable longer-term technical positioning, and a negative P/E ratio keep the overall score near the bottom of the range.
OncoZenge AB (ONCOZ) vs. iShares MSCI Sweden ETF (EWD)
- Market Cap
- SEK 89.57M
- Dividend Yield
- ―
- Average Volume (3M)
- 67.71K
- Price to Earnings (P/E)
- -1.4
- Beta (1Y)
- 1.45
- Revenue Growth
- 115.26%
- EPS Growth
- -230.43%
- Country
- Sweden
- Employees
- 1
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
OncoZenge AB Business Overview & Revenue Model
Company Description
OncoZenge AB (publ) operates as a pharmaceutical company with a focus on developing medical solutions that offer supportive care for cancer patients. A significant product in its pipeline is BupiZenge, which has successfully completed Phase 2 clinica...
OncoZenge AB Financial Statement Overview
Summary
Financial performance is weak overall: revenue declined 56.5%, EBIT and net margins were deeply negative, and operating cash flow remained substantially negative. Debt-free status and positive equity provide some support, but the underlying financial scores average below the minimum permitted component score.
Income Statement
15Very NegativeBalance Sheet
55NeutralCash Flow
25Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.81M | 2.66M | 1,000 | 3,000 | 0 | 0 |
| Gross Profit | 3.93M | -4.84M | 1,000 | 3,000 | 0 | 0 |
| EBITDA | -21.96M | -15.87M | -8.69M | 7.27M | 2.77M | -4.89M |
| Net Income | -31.92M | -15.94M | -8.69M | -15.90M | -46.65M | -3.89M |
Balance Sheet | ||||||
| Total Assets | 33.80M | 15.34M | 11.43M | 20.34M | 36.89M | 85.23M |
| Cash, Cash Equivalents and Short-Term Investments | 24.30M | 3.71M | 3.86M | 12.63M | 29.14M | 51.22M |
| Total Debt | 0 | 7.50M | 0 | 0 | 0 | 0 |
| Total Liabilities | 15.12M | 15.92M | 1.48M | 1.70M | 2.92M | 4.90M |
| Stockholders Equity | 18.68M | -587.00K | 9.95M | 18.64M | 33.97M | 80.32M |
Cash Flow | ||||||
| Free Cash Flow | -13.90M | -13.06M | -8.76M | -17.08M | -22.08M | -10.12M |
| Operating Cash Flow | -26.96M | -13.06M | -8.76M | -17.08M | -22.08M | -4.77M |
| Investing Cash Flow | 0 | 0 | 0 | 570.00K | 0 | -5.36M |
| Financing Cash Flow | 39.67M | 12.91M | 0 | 0 | 0 | 51.34M |
OncoZenge AB Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ONCOZ, the sentiment is Neutral. The current price of 3.25 is above the 20-day moving average (MA) of 3.18, below the 50-day MA of 3.34, and below the 200-day MA of 4.75, indicating a neutral trend. The MACD of -0.07 indicates Negative momentum. The RSI at 48.85 is Neutral, neither overbought nor oversold. The STOCH value of 74.04 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:ONCOZ.
OncoZenge AB Peers Comparison
Overall Rating
SE:CANTA61Neutral
SE:ISOFOL48Neutral
SE:ELIC45Neutral
SE:ONCO44Neutral
SE:IMMU39Underperform
SE:ONCOZ39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 61Neutral | SEK 391.34M | 2.04 | 63.09% | ― | ― | ― | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 48Neutral | SEK 326.26M | -5.09 | -58.68% | ― | ― | 35.02% | |
| 45Neutral | SEK 172.51M | -7.31 | -56.09% | ― | ― | 14.10% | |
| 44Neutral | SEK 763.50M | -2.81 | ― | ― | 65.37% | 43.28% | |
| 39Underperform | SEK 276.26M | -2.43 | -19.14% | ― | ― | 13.06% | |
| 39Underperform | SEK 89.57M | -1.38 | -970.69% | ― | 115.26% | -230.43% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SE:ONCOZ | OncoZenge AB | 3.25 | -1.68 | -34.07% | |
| SE:ONCO | Oncopeptides AB | 1.77 | -3.13 | -63.86% | |
| SE:ISOFOL | Isofol Medical AB | 1.02 | 0.32 | 45.85% | |
| SE:ELIC | Elicera Therapeutics AB | 2.58 | -2.68 | -50.86% | |
| SE:IMMU | Immunicum AB | 4.36 | -1.30 | -23.06% | |
| SE:CANTA | Cantargia AB | 1.39 | -2.06 | -59.77% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 13, 2026
